CYTOKINETICS, INCORPORATED Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
CYTOKINETICS, INCORPORATED (CYTK) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 0 shares for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-05.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2018-03-05
- CYTOKINETICS, INCORPORATED incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2017-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- CYTOKINETICS, INCORPORATED incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2016-09-30 was 2.40M shares.
- CYTOKINETICS, INCORPORATED incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2015-09-30 was 0.00 shares.
- CYTOKINETICS, INCORPORATED incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2017 was 0.00 shares, a 100.00% decline from fiscal 2016.
- CYTOKINETICS, INCORPORATED incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2016 was 2.02M shares.
- CYTOKINETICS, INCORPORATED incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2015 was 0.00 shares.
- CYTOKINETICS, INCORPORATED incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2014 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month |
|---|---|---|---|
| 2017-12-31 | 0.00 shares 10-K · filed 2018-03-05 | ||
| 2017-09-30 | 0.00 shares 10-Q · filed 2017-11-03 | 0.00 shares 10-Q · filed 2017-11-03 | |
| 2016-12-31 | 2.02M shares 10-K · filed 2018-03-05 | ||
| 2016-09-30 | 2.40M shares 10-Q · filed 2017-11-03 | 1.94M shares 10-Q · filed 2017-11-03 | |
| 2015-12-31 | 0.00 shares 10-K · filed 2018-03-05 | ||
| 2015-09-30 | 0.00 shares 10-Q/A · filed 2016-12-15 | 0.00 shares 10-Q/A · filed 2016-12-15 | |
| 2014-12-31 | 0.00 shares 10-K · filed 2017-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |